Finally, to investigate the effects of Juglone or KPT6566 treatment on tumor-initiating cell-induced tumorigenesis, the in vivo anti-tumorigenic properties of Juglone and KPT6566 were examined in NSG mice bearing CD44+CD133+ Caco-2 cell xenografts. The gene discussed is PROM1; the disease is neoplasm.